ArticleThe Lancet regional health. Southeast Asia2023

Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial.

Sanket Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.